News
NVO
126.15
-1.94%
-2.49
What Are Pricing Strategies for Ozempic And Wegovy With Potential Medicare Coverage Expansion? Senate Committee Questions Novo Nordisk
Senator Bernie Sanders wants to investigate Novo Nordisk A/S’s pricing strategies for diabetes and obesity medications. The Senate Committee on Health, Education, Labor, and Pensions is looking into the company's pricing discrepancies. Study suggests that Medicare may cover drugs approved for obesity and heart conditions.
Benzinga · 8h ago
Novo Nordisk Probed by Senate Committee on Weight-Loss Drug Prices
Sen. Bernie Sanders calls for reduced prices for Novo Nordisk's weight-loss drugs Ozempic and Wegovy. The company is being investigated by a U.S. Senate committee for the prices of the drugs. Sanders says the drugs are unaffordable for many patients. The drugs are currently not covered by Medicaid in 35 states.
Dow Jones · 8h ago
Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage
Madrigal Pharmaceuticals, Inc. Recently received FDA approval for its lead candidate resmetirom, targeting a liver condition called NASH. The NASH market is projected to reach $50 billion by 2035. The company will have to overcome two challenges to maintain its "first mover" advantage in the market. Madrigal has to manage the launch of Rezdiffra and keep an eye on future competitors.
Seeking Alpha · 9h ago
MEDIA-US Senate committee investigates Ozempic and Wegovy costs - NYT
Reuters · 10h ago
"Senate Committee Investigates Ozempic And Wegovy Costs; Senator Bernie Sanders Is Pressing The Drugmaker Novo Nordisk For Details On Its Pricing Of The Popular Diabetes And Weight Loss Medications" - NY Times
Benzinga · 10h ago
3.6M Medicare patients could qualify for Wegovy coverage: report
Seeking Alpha · 11h ago
4 Large Drug Stocks to Hold on to Amid Industry Challenges
NASDAQ · 12h ago
Artisan International Fund Q1 2024 Commentary
Seeking Alpha · 12h ago
VIGI: Blue Chip International Growth
Vanguard International Dividend Appreciation Index Fund is a blue-chip portfolio on non-US stocks. VIGI offers a potential total return upside of 13% on EPS growth of 8% valued at 17x PE or 2x PEG. The dividend appreciation strategy is a key filter in identifying consistent growth stocks at reasonable prices. Novo Nordisk is currently the largest weight in the portfolio.
Seeking Alpha · 12h ago
Artisan Global Equity Fund Q1 2024 Commentary
Seeking Alpha · 12h ago
Should Eli Lilly (LLY) Be in Your Portfolio Ahead of Q1 Earnings?
NASDAQ · 13h ago
About 3.6 mln Medicare beneficiaries could be eligible for Wegovy coverage, study shows
About 3.6 million overweight or obese patients with heart conditions could be eligible for coverage of weight-loss drug Wegovy. The drug was approved by the U.S. For lowering the risk of stroke and heart attack in overweight and obese adults. Study shows that about a quarter of the 13.7 million Medicare beneficiaries could use the drug.
Reuters · 17h ago
UPDATE 2-Roche eyes return to growth after Q1 hit by forex, loss of COVID sales
Roche eyes return to growth after Q1 hit by forex, loss of COVID sales, strong Swiss franc. First-quarter sales fell by 6% to 14.4 billion Swiss francs, in line with expectations. Swiss drugmaker sees continued boost from eye drug Vabysmo. Reiterates 2024 guidance of sales growth in "mid single-digit" percentage range.
Reuters · 20h ago
RPT-ANALYSIS-UK stocks may finally be back in fashion
London's FTSE-100 hit a record high on Tuesday. Britain's benchmark stock index touched a peak of 8,076.52, surpassing its previous high from February 2023. The FTSe-100 has long underperformed rival indexes. But rising commodity prices, a weaker pound and a pick-up in UK growth are encouraging investors.
Reuters · 21h ago
What to Watch in the Day Ahead - Wednesday, April 24
Meta Platforms' revenue is expected to grow 26% as AI investments drive higher engagement at Instagram. Boeing expected to report a much higher cash burn and its first revenue fall in seven quarters. AT&T expected to post weak subscriber additions in the first quarter. Census Bureau to report orders for durable goods rose 2.5% in March.
Reuters · 1d ago
ANALYSIS-UK stocks may finally be back in fashion
London's FTSE-100 hit a record high on Tuesday. Britain's benchmark stock index touched a peak of 8,076.52, surpassing its previous high from February 2023. The FTSe-100 has long underperformed compared to rival indexes. But rising commodity prices, a weaker pound, and UK growth are encouraging investors to return to UK stocks.
Reuters · 1d ago
3 Potential Biopharma Buyout Targets
Recent lack of M&A activity and rising interest rates have led to a 20% decline in small-cap biotech equities. Big Pharma's surplus of cash and key patent expirations should lead to increased M& a volume in the coming year. Three promising small biopharma names are attractive as standalone entities but would make logical buyout targets. Mirum Pharmaceuticals, Inc., ImmunoGen, Inc. And GLP-1 are three names that could be attractive.
Seeking Alpha · 1d ago
TikTok to restrict weight loss drug promotion
Seeking Alpha · 1d ago
PPH: Buy The Pullback In This Big Pharma ETF For Long-Term Total Returns
VanEck Pharmaceutical ETF is a popular option for investors looking for exposure to leading pharmaceutical companies. The ETF's top holdings include Eli Lilly, Novo Nordisk, and Johnson & Johnson. The fund has been in an uptrend since late last year and is currently trading at a level that presents a buying opportunity.
Seeking Alpha · 1d ago
Why Novo Nordisk Topped the Market Today
Danish pharmaceutical company Novo Nordisk bought 207,000 of its own shares last week. The company's shares rose more than 2% on the day. The Danish-based company is the company behind popular weight loss and diabetes drugs. It has a one-year stock buyback program.
The Motley Fool · 2d ago
More
Webull provides a variety of real-time NVO stock news. You can receive the latest news about Novo-Nordisk A/S through multiple platforms. This information may help you make smarter investment decisions.
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.